Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.
about
Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infectionsAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsClinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittiiBiopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. ColistinMucin Binding Reduces Colistin Antimicrobial Activity.Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and RifampicinSubstantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.To B or not to B, that is the question: is it time to replace colistin with polymyxin B?Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial.Colistin: efficacy and safety in different populations.Strategies for the safe use of colistin.Polymyxin B versus colistin: an update.Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder?Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Pulmonary Pharmacokinetics of Colistin Following Administration of Dry Powder Aerosols in Rats.Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.Potential Toxicity of Polymyxins in Human Lung Epithelial Cells.Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children.Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cellsTowards individualized diagnostics of biofilm-associated infections: a case study.Microbiota in Exhaled Breath Condensate and the Lung.Community Composition Determines Activity of Antibiotics against Multispecies Biofilms.Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.Novel antibiotic combinations proposed for treatment of Burkholderia cepacia complex infections.
P2860
Q26991886-0F45C25A-BD08-4FE8-BFD5-5A1CDD9482A1Q27015109-11A80BB7-2492-41E5-8872-C2D3F791578BQ33798301-E1E3FEDB-7285-4015-8221-CC5191A26FA2Q33798554-D6AE83A4-0944-4775-8FA5-0DCBE4108175Q36076096-06732396-7048-4891-B135-C6BF5EC63FB1Q36642374-373E5CDF-6668-4C7F-A7BF-C21C27946CECQ36653925-042BDEEE-BEC8-48E4-96C8-4D6B495A3E79Q37538748-17749F96-EC92-49CA-9FAB-E169FD2F7600Q38262873-901F9179-2E9C-418D-A024-B39107BEC751Q38394222-595157A3-4B28-4646-958D-583983887F18Q38514980-229C65D6-82EC-4378-AF26-AB1AFB9BA8F1Q38548658-59E22E8B-ABE8-4F4B-BA8C-17CCC55CFE4BQ38613051-59DB4C47-890B-4028-8077-CB55EC9471E5Q38677017-612F3E1B-A992-4D31-B6EA-4641538A3C85Q38755683-412E59F2-8477-4339-A555-6790722147D1Q38859067-966E7A66-F295-4492-B438-A869A5D77624Q38994000-4B542EB5-AB7A-4FBE-AE83-1AB481320F87Q39057108-FD0BEA01-2F93-40FD-9377-373462A53EB2Q39333751-023BA8F5-7234-425E-8D5B-D501E8E3EE2FQ40093588-B2B577B0-FD43-4516-B63B-349A08930407Q40234980-3C29C0E3-A4E2-4DAB-8A9F-499C9A36424EQ40248118-82B9E0E6-1602-4383-B5B0-8A5E707F4EF0Q40422166-4BACC171-CCF8-4EC0-9BCC-4A13497D3B46Q41027375-CEBC7938-6428-4C95-B65A-9807B873CF91Q41260939-4D5D1083-68D4-4919-8CFE-2FD986766851Q41736354-D3192158-F920-4422-8229-5EDE55F69E00Q41902328-4D5F28A1-F2BD-409E-A173-E71E75575D43Q42232425-9603EE9E-23BE-4BAA-B0DA-6C45316594F5Q46337701-FBC8A1CF-7995-46B3-BE23-C7B6D5089255Q47273930-D4BDA36A-ED85-4866-B5DA-92FD8A7D5EB6Q47327699-A223936B-6286-45A7-8294-80D2CF8DF768Q47391725-FB8FFA30-BB7F-4733-A118-9FA8918A2668Q47691122-703B3EB1-20B8-48A0-9F39-F1D3341695FC
P2860
Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pulmonary and systemic pharmac ...... f inhalational administration.
@en
Pulmonary and systemic pharmac ...... f inhalational administration.
@nl
type
label
Pulmonary and systemic pharmac ...... f inhalational administration.
@en
Pulmonary and systemic pharmac ...... f inhalational administration.
@nl
prefLabel
Pulmonary and systemic pharmac ...... f inhalational administration.
@en
Pulmonary and systemic pharmac ...... f inhalational administration.
@nl
P2093
P2860
P50
P356
P1476
Pulmonary and systemic pharmac ...... of inhalational administration
@en
P2093
Denise Clark
Elyssa Williams
John W Wilson
Kashyap Patel
Michael J Dooley
Shalini Yapa
Susan Poole
P2860
P304
P356
10.1128/AAC.01705-13
P407
P577
2014-02-18T00:00:00Z